{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:43Z","timestamp":1792465663383,"version":"4.5.0"},"reference-count":120,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>The cholinergic anti-inflammatory pathway is a part of the parasympathetic nervous system and it can also be entitled as an anti-inflammatory reflex. It consists of terminations of the vagal nerve into blood, acetylcholine released from the terminations, macrophages and other cells having \u03b17 nicotinic acetylcholine receptor (\u03b17 nAChR), calcium ions crossing through the receptor and interacting with nuclear factors, and erythrocytes with acetylcholinesterase (AChE) terminating the neurotransmission. Stopping of inflammatory cytokines production is the major task for the cholinergic antiinflammatory pathway. The cholinergic anti-inflammatory pathway can be stimulated or suppressed by agonizing or antagonizing \u03b17 nAChR or by inhibition of AChE. This review is focused on cholinergic anti-inflammatory pathway regulation by drugs. Compounds that inhibit cholinesterases (for instance, huperzine, rivastigmine, galantamine), and their impact on the cholinergic anti-inflammatory pathway are discussed here and a survey of actual literature is provided.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557520666201117111715","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:32:07Z","timestamp":1605760327000},"page":"660-669","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacological Influencing of The Cholinergic Anti-inflammatory Pathway in Infectious Diseases and Inflammatory Pathologies"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-8356","authenticated-orcid":true,"given":"Miroslav","family":"Pohanka","sequence":"first","affiliation":[{"name":"Faculty of Military Health Sciences, University of Defense, Trebesska 1575, Hradec Kralove CZ-50001,Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2015_169","volume":"884","author":"Winklewski P.J.","year":"2016","unstructured":"Winklewski P.J.; Radkowski M.; Demkow U.; Relevance of immune-sympathetic nervous system interplay for the development of hypertension. Adv Exp Med Biol 2016,884,37-43","journal-title":"Adv Exp Med Biol"},{"key":"ref=2","author":"Pongratz G.","year":"2014","unstructured":"Pongratz G.; Straub R.H.; The sympathetic nervous response in inflammation 2014","journal-title":"The sympathetic nervous response in inflammation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.05.007","volume":"321","author":"Noble B.T.","year":"2018","unstructured":"Noble B.T.; Brennan F.H.; Popovich P.G.; The spleen as a neuroimmune interface after spinal cord injury. J Neuroimmunol 2018,321,1-11","journal-title":"J Neuroimmunol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.expneurol.2014.04.023","volume":"258","author":"Schwab J.M.","year":"2014","unstructured":"Schwab J.M.; Zhang Y.; Kopp M.A.; Brommer B.; Popovich P.G.; The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. Exp Neurol 2014,258,121-129","journal-title":"Exp Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11481-015-9640-y","volume":"10","author":"Mosley R.L.","year":"2015","unstructured":"Mosley R.L.; Adaptive immunity in neurodegenerative and neuropsychological disorders. J Neuroimmune Pharmacol 2015,10(4),522-527","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11481-015-9639-4","volume":"10","author":"Gendelman H.E.","year":"2015","unstructured":"Gendelman H.E.; Mosley R.L.; A perspective on roles played by innate and adaptive immunity in the pathobiology of neurodegenerative disorders. J Neuroimmune Pharmacol 2015,10(4),645-650","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/09298673113206660258","volume":"21","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Alzheimer\u2019s disease and oxidative stress: A review. Curr Med Chem 2014,21(3),356-364","journal-title":"Curr Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2174\/0929867323666160418114733","volume":"23","author":"Pohanka M.","year":"2016","unstructured":"Pohanka M.; Vaccination to alzheimer disease. Is it a promising tool or a blind way? Curr Med Chem 2016,23(14),1432-1441","journal-title":"Curr Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3390\/ijms13022219","volume":"13","author":"Pohanka M.","year":"2012","unstructured":"Pohanka M.; Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 2012,13(2),2219-2238","journal-title":"Int J Mol Sci"},{"key":"ref=10","first-page":"373","volume":"2018","author":"Changeux J.P.","year":"1749","unstructured":"Changeux J.P.; The nicotinic acetylcholine receptor: A typical \u2018allosteric machine\u2019. Philos Trans R Soc Lond B Biol Sci 1749,2018,373","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"40207","DOI":"10.1074\/jbc.R112.407668","volume":"287","author":"Changeux J.P.","year":"2012","unstructured":"Changeux J.P.; The nicotinic acetylcholine receptor: The founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012,287(48),40207-40215","journal-title":"J Biol Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.irn.2015.07.001","volume":"124","author":"Dani J.A.","year":"2015","unstructured":"Dani J.A.; Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int Rev Neurobiol 2015,124,3-19","journal-title":"Int Rev Neurobiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00424-017-2050-7","volume":"470","author":"Criado M.","year":"2018","unstructured":"Criado M.; Acetylcholine nicotinic receptor subtypes in chromaffin cells. Pflugers Arch 2018,470(1),13-20","journal-title":"Pflugers Arch"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1073\/pnas.0600506103","volume":"103","author":"Pavlov V.A.","year":"2006","unstructured":"Pavlov V.A.; Ochani M.; Gallowitsch-Puerta M.; Ochani K.; Huston J.M.; Czura C.J.; Al-Abed Y.; Tracey K.J.; Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 2006,103(13),5219-5223","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2183\/pjab.89.226","volume":"89","author":"Haga T.","year":"2013","unstructured":"Haga T.; Molecular properties of muscarinic acetylcholine receptors. Proc Jpn Acad, Ser B, Phys Biol Sci 2013,89(6),226-256","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0165-6147(03)00195-0","volume":"24","author":"Wess J.","year":"2003","unstructured":"Wess J.; Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. Trends Pharmacol Sci 2003,24(8),414-420","journal-title":"Trends Pharmacol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.neuropharm.2017.11.023","volume":"136","author":"Marsango S.","year":"2018","unstructured":"Marsango S.; Ward R.J.; Alvarez-Curto E.; Milligan G.; Muscarinic receptor oligomerization. Neuropharmacology 2018,136(Pt C),401-410","journal-title":"Neuropharmacology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd4295","volume":"13","author":"Kruse A.C.","year":"2014","unstructured":"Kruse A.C.; Kobilka B.K.; Gautam D.; Sexton P.M.; Christopoulos A.; Wess J.; Muscarinic acetylcholine receptors: Novel opportunities for drug development. Nat Rev Drug Discov 2014,13(7),549-560","journal-title":"Nat Rev Drug Discov"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2014.02.006","volume":"16","author":"Kruse A.C.","year":"2014","unstructured":"Kruse A.C.; Hu J.; Kobilka B.K.; Wess J.; Muscarinic acetylcholine receptor X-ray structures: Potential implications for drug development. Curr Opin Pharmacol 2014,16,24-30","journal-title":"Curr Opin Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5507\/bp.2011.036","volume":"155","author":"Pohanka M.","year":"2011","unstructured":"Pohanka M.; Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011,155(3),219-229","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2174\/1389557517666170120153930","volume":"17","author":"Thapa S.","year":"2017","unstructured":"Thapa S.; Lv M.; Xu H.; Acetylcholinesterase: A primary target for drugs and insecticides. Mini Rev Med Chem 2017,17(17),1665-1676","journal-title":"Mini Rev Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1002\/chem.201805075","volume":"25","author":"Franjesevic A.J.","year":"2019","unstructured":"Franjesevic A.J.; Sillart S.B.; Beck J.M.; Vyas S.; Callam C.S.; Hadad C.M.; Resurrection and reactivation of acetylcholinesterase and butyrylcholinesterase. Chemistry 2019,25(21),5337-5371","journal-title":"Chemistry"},{"key":"ref=23","first-page":"726","volume":"114","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Butyrylcholinesterase as a biochemical marker. Bratisl Lek Listy 2013,114(12),726-734","journal-title":"Bratisl Lek Listy"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2174\/1567205013666160404120542","volume":"13","author":"Darvesh S.","year":"2016","unstructured":"Darvesh S.; Butyrylcholinesterase as a diagnostic and therapeutic target for alzheimer\u2019s disease. Curr Alzheimer Res 2016,13(10),1173-1177","journal-title":"Curr Alzheimer Res"},{"key":"ref=25","first-page":"279","volume":"74","author":"Delacour H.","year":"2016","unstructured":"Delacour H.; Dedome E.; Courcelle S.; Hary B.; Ceppa F.; Butyrylcholinesterase deficiency. Ann Biol Clin (Paris) 2016,74(3),279-285","journal-title":"Ann Biol Clin (Paris)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/qjmed\/hcy154","volume":"112","author":"Huang Y.","year":"2019","unstructured":"Huang Y.; Zhao C.; Su X.; Neuroimmune regulation of lung infection and inflammation. QJM 2019,112(7),483-487","journal-title":"QJM"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034199","volume":"9","author":"Bonaz B.","year":"2019","unstructured":"Bonaz B.; Sinniger V.; Pellissier S.; Vagus nerve stimulation at the interface of brain-gut interactions. Cold Spring Harb Perspect Med 2019,9(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nri2566","volume":"9","author":"Tracey K.J.","year":"2009","unstructured":"Tracey K.J.; Reflex control of immunity. Nat Rev Immunol 2009,9(6),418-428","journal-title":"Nat Rev Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2796.2009.02098.x","volume":"265","author":"Rosas-Ballina M.","year":"2009","unstructured":"Rosas-Ballina M.; Tracey K.J.; Cholinergic control of inflammation. J Intern Med 2009,265(6),663-679","journal-title":"J Intern Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.autneu.2013.12.007","volume":"182","author":"Martelli D.","year":"2014","unstructured":"Martelli D.; McKinley M.J.; McAllen R.M.; The cholinergic anti-inflammatory pathway: A critical review. Auton Neurosci 2014,182,65-69","journal-title":"Auton Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bcpt.12611","volume":"119","author":"Kanashiro A.","year":"2016","unstructured":"Kanashiro A.; Talbot J.; Peres R.S.; Pinto L.G.; Bassi G.S.; Cunha T.M.; Cunha F.Q.; Neutrophil recruitment and articular hyperalgesia in antigen-induced arthritis are modulated by the cholinergic anti-inflammatory pathway. Basic Clin Pharmacol Toxicol 2016,119(5),453-457","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3892\/mmr.2016.5904","volume":"14","author":"Li S.","year":"2016","unstructured":"Li S.; Zhou B.; Liu B.; Zhou Y.; Zhang H.; Li T.; Zuo X.; Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration. Mol Med Rep 2016,14(6),5057-5064","journal-title":"Mol Med Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF03402177","volume":"9","author":"Pavlov V.A.","year":"2003","unstructured":"Pavlov V.A.; Wang H.; Czura C.J.; Friedman S.G.; Tracey K.J.; The cholinergic anti-inflammatory pathway: A missing link in neuroimmunomodulation. Mol Med 2003,9(5-8),125-134","journal-title":"Mol Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2119\/2006-00108.Goldstein","volume":"13","author":"Goldstein R.S.","year":"2007","unstructured":"Goldstein R.S.; Bruchfeld A.; Yang L.; Qureshi A.R.; Gallowitsch-Puerta M.; Patel N.B.; Huston B.J.; Chavan S.; Rosas-Ballina M.; Gregersen P.K.; Czura C.J.; Sloan R.P.; Sama A.E.; Tracey K.J.; Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007,13(3-4),210-215","journal-title":"Mol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-019-0097-y","volume":"25","author":"Hilderman M.","year":"2019","unstructured":"Hilderman M.; Qureshi A.R.; Abtahi F.; Witt N.; J\u00e4gren C.; Olbers J.; Delle M.; Lindecrantz K.; Bruchfeld A.; The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation. Mol Med 2019,25(1),1-10","journal-title":"Mol Med"},{"key":"ref=36","author":"Frasch M.G.","year":"2016","unstructured":"Frasch M.G.; Szynkaruk M.; Prout A.P.; Nygard K.; Cao M.; Veldhuizen R.; Hammond R.; Richardson B.S.; 2016"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ckj\/sfv074","volume":"8","author":"Hilderman M.","year":"2015","unstructured":"Hilderman M.; Qureshi A.R.; Al-Abed Y.; Abtahi F.; Lindecrantz K.; Anderstam B.; Bruchfeld A.; Cholinergic anti-inflammatory pathway activity in dialysis patients: A role for neuroimmunomodulation? Clin Kidney J 2015,8(5),599-605","journal-title":"Clin Kidney J"},{"key":"ref=38","first-page":"121","volume":"107","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Biosensors based on cholinesterases. Chem Listy 2013,107(2),121-125","journal-title":"Chem Listy"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/00032719.2013.780240","volume":"46","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Cholinesterases in biorecognition and biosensor construction, a review. Anal Lett 2013,46(12),1849-1868","journal-title":"Anal Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2478\/s11696-014-0542-x","volume":"69","author":"Pohanka M.","year":"2015","unstructured":"Pohanka M.; Biosensors containing acetylcholinesterase and butyrylcholinesterase as recognition tools for detection of various compounds. Chem Pap 2015,69(1),4-16","journal-title":"Chem Pap"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.3390\/ijms15069809","volume":"15","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci 2014,15(6),9809-9825","journal-title":"Int J Mol Sci"},{"key":"ref=42","author":"Tanaka S.","year":"2019","unstructured":"Tanaka S.; Hammond B.; Rosin D.L.; Okusa M.D.; 2019"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1684\/ecn.2019.0426","volume":"30","author":"Wang D.","year":"2019","unstructured":"Wang D.; Gao T.; Zhao Y.; Mao Y.; Sheng Z.; Lan Q.; Nicotine exerts neuroprotective effects by attenuating local inflammatory cytokine production following crush injury to rat sciatic nerves. Eur Cytokine Netw 2019,30(2),59-66","journal-title":"Eur Cytokine Netw"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/CM9.0000000000000766","volume":"133","author":"Huang D.Y.","year":"2020","unstructured":"Huang D.Y.; Li Q.; Shi C.Y.; Hou C.Q.; Miao Y.; Shen H.B.; Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway. Chin Med J (Engl) 2020,133(9),1073-1079","journal-title":"Chin Med J (Engl)"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155019","volume":"128","author":"Wu X.J.","year":"2020","unstructured":"Wu X.J.; Yan X.T.; Yang X.M.; Zhang Y.; Wang H.Y.; Luo H.; Fang Q.; Li H.; Li X.Y.; Chen K.; Wang Y.L.; Zhang Z.Z.; Song X.M.; GTS-21 ameliorates polymicrobial sepsis-induced hepatic injury by modulating autophagy through \u03b17nAchRs in mice. Cytokine 2020,128(155019)","journal-title":"Cytokine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fphar.2017.00809","volume":"8","author":"Grandi A.","year":"2017","unstructured":"Grandi A.; Zini I.; Flammini L.; Cantoni A.M.; Vivo V.; Ballabeni V.; Barocelli E.; Bertoni S.; Alpha7 nicotinic agonist ar-r17779 protects mice against 2, 4,6-trinitrobenzene sulfonic acid-induced colitis in a spleen-dependent way. Front Pharmacol 2017,8(809),809","journal-title":"Front Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1476-5381.2010.00699.x","volume":"160","author":"Snoek S.A.","year":"2010","unstructured":"Snoek S.A.; Verstege M.I.; van der Zanden E.P.; Deeks N.; Bulmer D.C.; Skynner M.; Lee K.; Te Velde A.A.; Boeckxstaens G.E.; de Jonge W.J.; Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol 2010,160(2),322-333","journal-title":"Br J Pharmacol"},{"key":"ref=48","author":"Padilla A.","year":"2017","unstructured":"Padilla A.; Keating P.; Hartmann J.X.; Mari F.; Effects of alpha-conotoxin imi on tnf-alpha, il-8 and tgf-beta expression by human macrophage-like cells derived from thp-1 pre-monocytic leukemic cells 2017","journal-title":"Effects of alpha-conotoxin imi on tnf-alpha, il-8 and tgf-beta expression by human macrophage-like cells derived from thp-1 pre-monocytic leukemic cells"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.neuron.2020.03.012","volume":"106","author":"Rahman M.M.","year":"2020","unstructured":"Rahman M.M.; Teng J.; Worrell B.T.; Noviello C.M.; Lee M.; Karlin A.; Stowell M.H.B.; Hibbs R.E.; Structure of the native muscle-type nicotinic receptor and inhibition by snake venom toxins. Neuron 2020,106(6),952-962","journal-title":"Neuron"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/mol.119.117713","volume":"96","author":"Lebedev D.S.","year":"2019","unstructured":"Lebedev D.S.; Kryukova E.V.; Ivanov I.A.; Egorova N.S.; Timofeev N.D.; Spirova E.N.; Tufanova E.Y.; Siniavin A.E.; Kudryavtsev D.S.; Kasheverov I.E.; Zouridakis M.; Katsarava R.; Zavradashvili N.; Iagorshvili I.; Tzartos S.J.; Tsetlin V.I.; Oligoarginine peptides, a new family of nicotinic acetylcholine receptor inhibitors. Mol Pharmacol 2019,96(5),664-673","journal-title":"Mol Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.12.014","volume":"117","author":"Kanashiro A.","year":"2017","unstructured":"Kanashiro A.; S\u00f4nego F.; Ferreira R.G.; Castanheira F.V.; Leite C.A.; Borges V.F.; Nascimento D.C.; C\u00f3lon D.F.; Alves-Filho J.C.; Ulloa L.; Cunha F.Q.; Therapeutic potential and limitations of cholinergic anti-inflammatory pathway in sepsis. Pharmacol Res 2017,117,1-8","journal-title":"Pharmacol Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.15171\/apb.2017.063","volume":"7","author":"Hajiasgharzadeh K.","year":"2017","unstructured":"Hajiasgharzadeh K.; Baradaran B.; Cholinergic anti-inflammatory pathway and the liver. Adv Pharm Bull 2017,7(4),507-513","journal-title":"Adv Pharm Bull"},{"key":"ref=53","first-page":"68","volume":"45","author":"Zi S.","year":"2020","unstructured":"Zi S.; Li J.; Liu L.; Liu F.; Cholinergic anti-inflammatory pathway and its role in treatment of sepsis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020,45(1),68-73","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1097\/CCM.0000000000002646","volume":"45","author":"Zhai Q.","year":"2017","unstructured":"Zhai Q.; Lai D.; Cui P.; Zhou R.; Chen Q.; Hou J.; Su Y.; Pan L.; Ye H.; Zhao J.W.; Fang X.; Selective activation of basal forebrain cholinergic neurons attenuates polymicrobial sepsis-induced inflammation via the cholinergic anti-inflammatory pathway. Crit Care Med 2017,45(10),e1075-e1082","journal-title":"Crit Care Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fphar.2011.00023","volume":"2","author":"Zhao T.","year":"2011","unstructured":"Zhao T.; Li D.J.; Liu C.; Su D.F.; Shen F.M.; Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway. Front Pharmacol 2011,2(23),23","journal-title":"Front Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semnephrol.2015.01.005","volume":"35","author":"Swaminathan S.","year":"2015","unstructured":"Swaminathan S.; Rosner M.H.; Okusa M.D.; Emerging therapeutic targets of sepsis-associated acute kidney injury. Semin Nephrol 2015,35(1),38-54","journal-title":"Semin Nephrol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.immuni.2017.06.008","volume":"46","author":"Chavan S.S.","year":"2017","unstructured":"Chavan S.S.; Pavlov V.A.; Tracey K.J.; Mechanisms and therapeutic relevance of neuro-immune communication. Immunity 2017,46(6),927-942","journal-title":"Immunity"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.phrs.2017.10.005","volume":"128","author":"Gomes J.P.","year":"2018","unstructured":"Gomes J.P.; Watad A.; Shoenfeld Y.; Nicotine and autoimmunity: The lotus\u2019 flower in tobacco. Pharmacol Res 2018,128,101-109","journal-title":"Pharmacol Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.trci.2019.03.004","volume":"5","author":"Eldufani J.","year":"2019","unstructured":"Eldufani J.; Blaise G.; The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Alzheimers Dement (N Y) 2019,5,175-183","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=60","first-page":"1479","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. [Review Mol Med Rep 2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1177\/0269881118805496","volume":"32","author":"Santos B.","year":"2018","unstructured":"Santos B.; Gonz\u00e1lez-Fraile E.; Zabala A.; Guill\u00e9n V.; Rueda J.R.; Ballesteros J.; Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. J Psychopharmacol (Oxford) 2018,32(11),1155-1166","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/13543776.2017.1272571","volume":"27","author":"McHardy S.F.","year":"2017","unstructured":"McHardy S.F.; Wang H.L.; McCowen S.V.; Valdez M.C.; Recent advances in acetylcholinesterase inhibitors and reactivators: An update on the patent literature (2012-2015). Expert Opin Ther Pat 2017,27(4),455-476","journal-title":"Expert Opin Ther Pat"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.2174\/0929867324666170705123509","volume":"24","author":"Lazarevic-Pasti T.","year":"2017","unstructured":"Lazarevic-Pasti T.; Leskovac A.; Momic T.; Petrovic S.; Vasic V.; Modulators of acetylcholinesterase activity: From alzheimer\u2019s disease to anti-cancer drugs. Curr Med Chem 2017,24(30),3283-3309","journal-title":"Curr Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/18715273113126660166","volume":"13","author":"Shaikh S.","year":"2014","unstructured":"Shaikh S.; Verma A.; Siddiqui S.; Ahmad S.S.; Rizvi S.M.; Shakil S.; Biswas D.; Singh D.; Siddiqui M.H.; Shakil S.; Tabrez S.; Kamal M.A.; Current acetylcholinesterase-inhibitors: A neuroinformatics perspective. CNS Neurol Disord Drug Targets 2014,13(3),391-401","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"Anand P.","year":"2013","unstructured":"Anand P.; Singh B.; A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch Pharm Res 2013,36(4),375-399","journal-title":"Arch Pharm Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2016.1216972","volume":"25","author":"Galimberti D.","year":"2016","unstructured":"Galimberti D.; Scarpini E.; Old and new acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Expert Opin Investig Drugs 2016,25(10),1181-1187","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.toxlet.2019.12.010","volume":"321","author":"Whitmore C.","year":"2020","unstructured":"Whitmore C.; Lindsay C.D.; Bird M.; Gore S.J.; Rice H.; Williams R.L.; Timperley C.M.; Green A.C.; Assessment of false transmitters as treatments for nerve agent poisoning. Toxicol Lett 2020,321,21-31","journal-title":"Toxicol Lett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1093\/milmed\/usz441","volume":"185","author":"Therkorn J.","year":"2020","unstructured":"Therkorn J.; Drewry D.G.; Tiburzi O.; Astatke M.; Young C.; Rainwater-Lovett K.; Review of biomarkers and analytical methods for organophosphate pesticides and applicability to nerve agents. Mil Med 2020,185(3-4),e414-e421","journal-title":"Mil Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/15376516.2011.589089","volume":"21","author":"Pohanka M.","year":"2011","unstructured":"Pohanka M.; Novotny L.; Pikula J.; Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of Wistar rats. Toxicol Mech Methods 2011,21(8),585-590","journal-title":"Toxicol Mech Methods"},{"key":"ref=70","author":"L\u00f3pez-Arrieta J.M.","year":"2006","unstructured":"L\u00f3pez-Arrieta J.M.; Schneider L.; Metrifonate for Alzheimer\u2019s disease. Cochrane Database Syst Rev 2006(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=71","volume":"6","author":"Kramer C.V.","year":"2014","unstructured":"Kramer C.V.; Zhang F.; Sinclair D.; Olliaro P.L.; Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2014,6(8)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=72","volume":"2","author":"Squires N.","year":"2000","unstructured":"Squires N.; Interventions for treating schistosomiasis haematobium. Cochrane Database Syst Rev 2000,2(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fimmu.2018.00551","volume":"9","author":"Al-Barazie R.M.","year":"2018","unstructured":"Al-Barazie R.M.; Bashir G.H.; Qureshi M.M.; Mohamed Y.A.; Al-Sbiei A.; Tariq S.; Lammers W.J.; Al-Ramadi B.K.; Fernandez-Cabezudo M.J.; Cholinergic activation enhances resistance to oral salmonella infection by modulating innate immune defense mechanisms at the intestinal barrier. Front Immunol 2018,9(551),551","journal-title":"Front Immunol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2567.2009.03238.x","volume":"130","author":"Fernandez-Cabezudo M.J.","year":"2010","unstructured":"Fernandez-Cabezudo M.J.; Lorke D.E.; Azimullah S.; Mechkarska M.; Hasan M.Y.; Petroianu G.A.; al-Ramadi B.K.; Cholinergic stimulation of the immune system protects against lethal infection by Salmonella enterica serovar Typhimurium. Immunology 2010,130(3),388-398","journal-title":"Immunology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bioorg.2016.06.002","volume":"67","author":"Bacalhau P.","year":"2016","unstructured":"Bacalhau P.; San Juan A.A.; Goth A.; Caldeira A.T.; Martins R.; Burke A.J.; Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR). Bioorg Chem 2016,67,105-109","journal-title":"Bioorg Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.bmc.2016.02.033","volume":"24","author":"Pejchal V.","year":"2016","unstructured":"Pejchal V.; \u0160t\u011bp\u00e1nkov\u00e1 \u0160.; Pejchalov\u00e1 M.; Kr\u00e1lovec K.; Havelek R.; R\u016f\u017ei\u010dkov\u00e1 Z.; Ajani H.; Lo R.; Lep\u0161\u00edk M.; Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors. Bioorg Med Chem 2016,24(7),1560-1572","journal-title":"Bioorg Med Chem"},{"key":"ref=77","author":"Ray B.","year":"2020","unstructured":"Ray B.; Maloney B.; Sambamurti K.; Karnati H.K.; Nelson P.T.; Greig N.H.; Lahiri D.K.; Rivastigmine modifies the \u03b1-secretase pathway and potentially early alzheimer's disease 2020","journal-title":"Rivastigmine modifies the \u03b1-secretase pathway and potentially early alzheimer's disease"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/acschemneuro.5b00040","volume":"6","author":"Mohamed L.A.","year":"2015","unstructured":"Mohamed L.A.; Qosa H.; Kaddoumi A.; Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem Neurosci 2015,6(5),725-736","journal-title":"ACS Chem Neurosci"},{"key":"ref=79","first-page":"1317","volume":"6","author":"Pohanka M.","year":"2012","unstructured":"Pohanka M.; Pavlis O.; Neostigmine modulates tularemia progression in balb\/c mice. Afr J Pharm Pharmacol 2012,6(17),1317-1322","journal-title":"Afr J Pharm Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s11481-017-9735-8","volume":"12","author":"Shifrin H.","year":"2017","unstructured":"Shifrin H.; Mouhadeb O.; Gluck N.; Varol C.; Weinstock M.; Cholinergic anti-inflammatory pathway does not contribute to prevention of ulcerative colitis by novel indoline carbamates. J Neuroimmune Pharmacol 2017,12(3),484-491","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/BCR.0000000000000068","volume":"36","author":"Hernekamp F.","year":"2015","unstructured":"Hernekamp F.; Klein H.; Schmidt K.; Vogelpohl J.; Kneser U.; Kremer T.; Microcirculatory effects of physostigmine on experimental burn edema. J Burn Care Res 2015,36(2),279-286","journal-title":"J Burn Care Res"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109318","volume":"118","author":"Pinder N.","year":"2019","unstructured":"Pinder N.; Zimmermann J.B.; Gastine S.; W\u00fcrthwein G.; Hempel G.; Bruckner T.; Hoppe-Tichy T.; Weigand M.A.; Swoboda S.; Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic\/pharmacodynamic study with population pharmacokinetic modeling. Biomed Pharmacother 2019,118(109318)","journal-title":"Biomed Pharmacother"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.2174\/1389557519666191018170908","volume":"18","author":"Pohanka M.","year":"2019","unstructured":"Pohanka M.; Inhibitors of cholinesterases in the pharmacology, the current trends. Mini Rev Med Chem 2019,18(10)","journal-title":"Mini Rev Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4155\/fmc.11.67","volume":"3","author":"da Silva V.B.","year":"2011","unstructured":"da Silva V.B.; de Andrade P.; Kawano D.F.; Morais P.A.B.; de Almeida J.R.; Carvalho I.; Taft C.A.; da Silva C.H.; In silico design and search for acetylcholinesterase inhibitors in Alzheimer\u2019s disease with a suitable pharmacokinetic profile and low toxicity. Future Med Chem 2011,3(8),947-960","journal-title":"Future Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","volume":"7","author":"Rainer M.","year":"1997","unstructured":"Rainer M.; Galanthamine in Alzheimer\u2019s disease: A new alternative to tacrine? CNS Drugs 1997,7(2),89-97","journal-title":"CNS Drugs"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","volume":"8","author":"Lilienfeld S.","year":"2002","unstructured":"Lilienfeld S.; Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease. CNS Drug Rev 2002,8(2),159-176","journal-title":"CNS Drug Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156720510790274455","volume":"7","author":"Darreh-Shori T.","year":"2010","unstructured":"Darreh-Shori T.; Soininen H.; Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer\u2019s disease: A review of recent clinical studies. Curr Alzheimer Res 2010,7(1),67-73","journal-title":"Curr Alzheimer Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","volume":"46","author":"Thomsen T.","year":"1990","unstructured":"Thomsen T.; Kewitz H.; Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990,46(21),1553-1558","journal-title":"Life Sci"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026039","volume":"6","author":"Berg L.","year":"2011","unstructured":"Berg L.; Andersson C.D.; Artursson E.; H\u00f6rnberg A.; Tunemalm A.K.; Linusson A.; Ekstr\u00f6m F.; Targeting acetylcholinesterase: identification of chemical leads by high throughput screening, structure determination and molecular modeling. PLoS One 2011,6(11)","journal-title":"PLoS One"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1517\/14656566.2013.760543","volume":"14","author":"Cheewakriengkrai L.","year":"2013","unstructured":"Cheewakriengkrai L.; Gauthier S.; A 10-year perspective on donepezil. Expert Opin Pharmacother 2013,14(3),331-338","journal-title":"Expert Opin Pharmacother"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.2174\/156802611798184409","volume":"11","author":"Rampa A.","year":"2011","unstructured":"Rampa A.; Belluti F.; Gobbi S.; Bisi A.; Hybrid-based multi-target ligands for the treatment of Alzheimer\u2019s disease. Curr Top Med Chem 2011,11(22),2716-2730","journal-title":"Curr Top Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/0929867003375281","volume":"7","author":"Bai D.L.","year":"2000","unstructured":"Bai D.L.; Tang X.C.; He X.C.; Huperzine A, a potential therapeutic agent for treatment of Alzheimer\u2019s disease. Curr Med Chem 2000,7(3),355-374","journal-title":"Curr Med Chem"},{"key":"ref=93","first-page":"413","volume":"19","author":"Liu J.","year":"1998","unstructured":"Liu J.; Zhang H.Y.; Tang X.C.; Wang B.; He X.C.; Bai D.L.; Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance. Zhongguo Yao Li Xue Bao 1998,19(5),413-416","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.ejmech.2011.03.058","volume":"46","author":"Luo W.","year":"2011","unstructured":"Luo W.; Li Y.P.; He Y.; Huang S.L.; Li D.; Gu L.Q.; Huang Z.S.; Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents. Eur J Med Chem 2011,46(6),2609-2616","journal-title":"Eur J Med Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1211\/jpp.59.9.0003","volume":"59","author":"Jogani V.V.","year":"2007","unstructured":"Jogani V.V.; Shah P.J.; Mishra P.; Mishra A.K.; Misra A.R.; Nose-to-brain delivery of tacrine. J Pharm Pharmacol 2007,59(9),1199-1205","journal-title":"J Pharm Pharmacol"},{"key":"ref=96","first-page":"S22","volume":"8","author":"Knapp M.J.","year":"1994","unstructured":"Knapp M.J.; Gracon S.I.; Davis C.S.; Solomon P.R.; Pendlebury W.W.; Knopman D.S.; Efficacy and safety of high-dose tacrine - a 30 week evaluation Alzheimer Dis. Assoc Dis 1994,8,S22-S31","journal-title":"Assoc Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","volume":"327","author":"Davis K.L.","year":"1992","unstructured":"Davis K.L.; Thal L.J.; Gamzu E.R.; Davis C.S.; Woolson R.F.; Gracon S.I.; Drachman D.A.; Schneider L.S.; Whitehouse P.J.; Hoover T.M.; Morris J.C.; Kawas C.H.; Knopman D.S.; Earl N.L.; Kumar V.; Doody R.S.; A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer\u2019s disease. N Engl J Med 1992,327(18),1253-1259","journal-title":"N Engl J Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/00032719.2012.757703","volume":"46","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Spectrophotomeric assay of aflatoxin b1 using acetylcholinesterase immobilized on standard microplates. Anal Lett 2013,46(8),1306-1315","journal-title":"Anal Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00604-010-0317-1","volume":"170","author":"Arduini F.","year":"2010","unstructured":"Arduini F.; Amine A.; Moscone D.; Palleschi G.; Biosensors based on cholinesterase inhibition for insecticides, nerve agents and aflatoxin b-1 detection. Mikrochim Acta 2010,170(3-4),193-214","journal-title":"Mikrochim Acta"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.3390\/ijms14059873","volume":"14","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Dobes P.; Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. Int J Mol Sci 2013,14(5),9873-9882","journal-title":"Int J Mol Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2174\/1389557514666140529223436","volume":"14","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; The effects of caffeine on the cholinergic system. Mini Rev Med Chem 2014,14(6),543-549","journal-title":"Mini Rev Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/sj.bjp.0706221","volume":"145","author":"Texid\u00f3 L.","year":"2005","unstructured":"Texid\u00f3 L.; Ros E.; Mart\u00edn-Satu\u00e9 M.; L\u00f3pez S.; Aleu J.; Marsal J.; Solsona C.; Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 2005,145(5),672-678","journal-title":"Br J Pharmacol"},{"key":"ref=103","author":"Ibrahim S.M.","year":"2018","unstructured":"Ibrahim S.M.; Al-Shorbagy M.Y.; Abdallah D.M.; El-Abhar H.S.; 2018"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4149\/BLL_2015_106","volume":"116","author":"Pohanka M.","year":"2015","unstructured":"Pohanka M.; The perspective of caffeine and caffeine derived compounds in therapy. Bratisl Lek Listy 2015,116(9),520-530","journal-title":"Bratisl Lek Listy"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.fsi.2019.12.028","volume":"97","author":"Wu N.","year":"2020","unstructured":"Wu N.; Xu X.; Wang B.; Li X.M.; Cheng Y.Y.; Li M.; Xia X.Q.; Zhang Y.A.; Anti-foodborne enteritis effect of galantamine potentially via acetylcholine anti-inflammatory pathway in fish. Fish Shellfish Immunol 2020,97,204-215","journal-title":"Fish Shellfish Immunol"},{"key":"ref=106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113665","volume":"170","author":"Gowayed M.A.","year":"2019","unstructured":"Gowayed M.A.; Rothe K.; Rossol M.; Attia A.S.; Wagner U.; Baerwald C.; El-Abhar H.S.; Refaat R.; The role of \u03b17nAChR in controlling the anti-inflammatory\/anti-arthritic action of galantamine. Biochem Pharmacol 2019,170(113665)","journal-title":"Biochem Pharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mad.2012.12.005","volume":"134","author":"Ruan Q.","year":"2013","unstructured":"Ruan Q.; Liu F.; Gao Z.; Kong D.; Hu X.; Shi D.; Bao Z.; Yu Z.; The anti-inflamm-aging and hepatoprotective effects of huperzine A in D-galactose-treated rats. Mech Ageing Dev 2013,134(3-4),89-97","journal-title":"Mech Ageing Dev"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.07.009","volume":"631","author":"Zhu S.Z.","year":"2016","unstructured":"Zhu S.Z.; Huang W.P.; Huang L.Q.; Han Y.L.; Han Q.P.; Zhu G.F.; Wen M.Y.; Deng Y.Y.; Zeng H.K.; Huperzine A protects sepsis associated encephalopathy by promoting the deficient cholinergic nervous function. Neurosci Lett 2016,631,70-78","journal-title":"Neurosci Lett"},{"key":"ref=109","first-page":"450","volume":"28","author":"Huang W.","year":"2016","unstructured":"Huang W.; Zhu S.; Liu X.; Huang L.; Han Y.; Han Q.; Xie D.; Zeng H.; Cholinergic anti-inflammatory pathway involves in the neuroprotective effect of huperzine A on sepsis-associated encephalopathy. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2016,28(5),450-454","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jneuroim.2019.04.012","volume":"332","author":"Maroli A.","year":"2019","unstructured":"Maroli A.; Di Lascio S.; Drufuca L.; Cardani S.; Setten E.; Locati M.; Fornasari D.; Benfante R.; Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: A possible link to the cholinergic anti-inflammatory pathway. J Neuroimmunol 2019,332,155-166","journal-title":"J Neuroimmunol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2016.06.053","volume":"789","author":"Arikawa M.","year":"2016","unstructured":"Arikawa M.; Kakinuma Y.; Noguchi T.; Todaka H.; Sato T.; Donepezil, an acetylcholinesterase inhibitor, attenuates LPS-induced inflammatory response in murine macrophage cell line RAW 264.7 through inhibition of nuclear factor kappa B translocation. Eur J Pharmacol 2016,789,17-26","journal-title":"Eur J Pharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4149\/BLL_2014_135","volume":"115","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Caffeine alters oxidative homeostasis in the body of BALB\/c mice. Bratisl Lek Listy 2014,115(11),699-703","journal-title":"Bratisl Lek Listy"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jab.2014.09.001","volume":"13","author":"Pohanka M.","year":"2015","unstructured":"Pohanka M.; Caffeine downregulates antibody production in a mouse model. J Appl Biomed 2015,13(1),1-6","journal-title":"J Appl Biomed"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1039\/D0GC00140F","volume":"22","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Meng Y.N.; Huang X.J.; Qin F.H.; Wu D.; Shao Q.; Guo Z.; Li Q.; Wei W.T.; Radical cyclization of 1,6-dienes with azobis(alkylcarbonitriles) on water under additive-free conditions. Green Chem 2020,22,4593-4596","journal-title":"Green Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/adsc.201901274","volume":"362","author":"B\u00f6hmer W.","year":"2020","unstructured":"B\u00f6hmer W.; Volkov A.; Engelmark Cassimjee K.; Mutti F.G.; Front cover picture: Continuous flow bioamination of ketones in organic solvents at controlled water activity using immobilized \u03c9-transaminases. Adv Synth Catal 2020,362(9),1858-1867","journal-title":"Adv Synth Catal"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"14153","DOI":"10.1021\/acssuschemeng.9b02822","volume":"16","author":"Xie L.Y.","year":"2019","unstructured":"Xie L.Y.; Jiang L.L.; Tan J.X.; Wang Y.; Xu X.Q.; Zhang B.; Cao Z.; He W.M.; Visible-light-initiated decarboxylative alkylation of quinoxalin-2(1h)-ones with phenyliodine(iii) dicarboxylates in recyclable ruthenium(ii) catalytic system. ACS Sustain Chem 2019,16,14153-14160","journal-title":"ACS Sustain Chem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1021\/acssuschemeng.8b05100","volume":"5","author":"Vadodariya N.","year":"2019","unstructured":"Vadodariya N.; Meena R.; Protein-functionalized aerogel membranes for gravity-driven separation. ACS Sustain Chem 2019,5,4814-4820","journal-title":"ACS Sustain Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1039\/D0GC01088J","volume":"22","author":"Kang Q.Q.","year":"2020","unstructured":"Kang Q.Q.; Wu W.; Li Q.; Wei W.T.; Photochemical strategies for c\u2013n bond formation via metal catalyst-free (hetero) aryl c(sp2)\u2013h functionalization. Green Chem 2020,22,3060-33068","journal-title":"Green Chem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1039\/D0GC00865F","volume":"22","author":"Huang X.J.","year":"2020","unstructured":"Huang X.J.; Qin F.H.; Wu S.P.; Li Q.; Wei W.T.; Acylation\/cyclization of 1,6-dienes with ethers under catalyst- and base-free conditions. Green Chem 2020,22,3952-3955","journal-title":"Green Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1039\/C9GC03769A","volume":"22","author":"Meng X.X.","year":"2020","unstructured":"Meng X.X.; Kang Q.Q.; Zhang J.Y.; Li Q.; Wei W.T.; He W.M.; Visible-light-initiated regioselective sulfonylation\/cyclization of 1,6-enynes under photocatalyst- and additive-free conditions. Green Chem 2020,22,1388-1392","journal-title":"Green Chem"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666201117111715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188083\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666201117111715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T01:57:51Z","timestamp":1698371871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188083\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666201117111715","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}